A Phase 4 interventional study of Moxidectin 2 MG Oral Tablet and Placebo in Blepharitis, sponsored by Eye Research Foundation, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-12.
Sponsored by Eye Research Foundation, Inc. · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 39 studies in Blepharitis with a site in United States — 5 open to participants now, 6 under way, none of them phase 3. Blepharitis · United States.
Among the 39 studies in Blepharitis with a site in United States, this one is the 29th largest by enrollment of the 37 interventional ones that give a count, is one of 2 that started in 2025, is one of 11 in phase 4, and was the 35th registered.
73 studies on the registry are indexed under Blepharitis; 9 are open to participants now.
Browse Blepharitis studies →5 of the 39 studies in Blepharitis with a site in United States are open now. Recruiting first, the newest first:
Brent Kramer · Sites in United States
Ages 18+
Glaukos Corporation · Sites in United States
Ages 18+
Olympic Ophthalmics, Inc. · Sites in United States
Ages 18+
University of Notre Dame · Sites in United States
Ages 18+ · Healthy volunteers
Brent Kramer · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 6 Blepharitis studies recruiting now, 6 set no upper age limit and none stop at 75 or younger; none take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
39 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 11 · Phase 3 5 · Phase 4 11
First in 2001; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 24 is below the median of 60 across 65 interventional studies indexed under Blepharitis.
Median enrollment 60 across the 37 interventional studies, 330 across the 2 observational. Of the 32 that completed or were terminated, 12 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 39 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Eye Research Foundation, Inc. as lead sponsor.
Eye Research Foundation, Inc. has 1 study filed under Blepharitis — fewer than ten, so there is no comparison to draw.
2 of the studies in Blepharitis with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07856680Brent KramerClinical Lid Eradication of Antifungal-Responsive FUNGUS Study | 2027-03 |
| NCT07869498Brent KramerOcular Dysbiosis in Eyelid Disease | 2027-03 |
Add all 2 to your calendar (.ics) → With an account.
Among the 39 studies in Blepharitis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A Single-Center, Investigator-Masked, Randomized, Placebo-Controlled, Investigator Initiated Study of the Safety and Efficacy of Moxidectin Tablets for the Reduction of Demodex Eyelash Infestation
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
- Active blepharitis with collarettes
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Moxidectin 2 MG Oral Tablet
Drug: Moxidectin 2 MG Oral Tablet · Drug: Placebo
Drug: Placebo
active medication
placebo pills
Collarette count
Collarette Count
Time frame: 6 weels
Plan to share: No
No publications or documents are linked to this record.
Ran from Feb 2025 to primary completion in Apr 2025, 2 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Moxidectin